此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RF GP Ablation Added to PEF PVI for Paroxysmal AF (REGATTA-AF)

2026年11月11日 更新者:Predrag Stojadinovic、Institute for Clinical and Experimental Medicine

RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation (REGATTA-AF Study)

This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.

The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.

研究概览

详细说明

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.

The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.

The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.

研究类型

介入性

注册 (估计的)

250

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Prague
      • Prague、Prague、捷克语、14200
        • Institute for Clinical and Experimental Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:

    1. Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
    2. Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
  2. Patients who are ≥30 and ≤65 years of age on the day of enrolment.

  3. Patients who are willing and capable of:

    1. Providing informed consent to undergo study procedures AND
    2. Participating in all examinations, follow-up visits, and tests associated with this clinical study.
  4. Effective contraception for women of childbearing potential.

  5. Effective oral anticoagulation for >3 weeks before the planned ablation procedure.

Exclusion Criteria:

  1. Persistent, long-standing persistent, or permanent AF.
  2. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
  3. Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
  4. Left ventricular ejection fraction <40%.
  5. Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
  6. Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
  7. Any prior atrial surgery.
  8. Intra-atrial septal patch or interatrial shunt.
  9. General contraindications of catheter ablation
  10. LA appendage closure, device, or occlusion, past or anticipated.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:RF GP + PEF PVI

Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field

isolation of pulmonary veins and roof line ablation using pulsed electric energy

ablation of GP using radiofrequency energy

有源比较器:PEF PVI

Pulmonary vein isolation and roof line ablation using pulsed electric field energy

isolation of pulmonary veins and roof line ablation using pulsed electric energy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Freedom from recurrent AF/AT >30 s during the first 12 months
大体时间:From the ablation procedure through the 12-month follow-up.

The primary outcome of the study is freedom from recurrent AF/AT >30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs.

From the ablation procedure through the 12-month follow-up.

次要结果测量

结果测量
措施说明
大体时间
Quality of life
大体时间:Baseline and at the 12-month visit.

This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life).

Baseline and at the 12-month visit.
Periprocedural complications, MACE
大体时间:From the ablation procedure through the 12-month follow-up.

periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up

From the ablation procedure through the 12-month follow-up.
Acute vagal denervation assessed by ECVS
大体时间:Periprocedural

ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded.

Periprocedural
Long-term cardiac vagal denervation
大体时间:Baseline and at the 12-month visit.

Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection.

Baseline and at the 12-month visit.
Vagal atrial induction test (VAFIT)
大体时间:Periprocedural

This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS.

Periprocedural

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年4月1日

初级完成 (估计的)

2028年4月1日

研究完成 (估计的)

2029年4月1日

研究注册日期

首次提交

2026年3月14日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅